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Are We at the Precipice of a Disruptive Innovation?*Nir Uriel, MD, MSC,y Sirtaz Adatya, MD,y Mandeep R. Mehra, MDz“It ought to be remembered that there is nothing
more difﬁcult to take in hand, more perilous
to conduct, or more uncertain in its success,
than to take the lead in the introduction of
a new order of things.”
—Niccolò Machiavelli (1)SEE PAGE 2579T he growing population with advanced stageheart failure (HF) is exempliﬁed by a highdisease burden, greater medical resource
utilization, lack of responsiveness to traditional
disease-modifying approaches, and an imperative
for specialized therapy, including cardiac transplan-
tation and durable mechanical circulatory support in
selected individuals (2). In recent years, left ventricu-
lar assist devices (LVADs) have become increasingly
entrenched into clinical practice as a result of transi-
tion from larger devices with displacement chambers
that mimicked ventricular function to smaller, more
durable devices with fewer moving parts that rely
on axial or centrifugal continuous ﬂow (3).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the yUniversity of Chicago Medical Center, Department of Medi-
cine, Cardiology Division, University of Chicago, Chicago, Illinois; and the
zBrigham and Women’s Hospital, Department of Medicine, Harvard
University, Boston, Massachusetts. Drs. Uriel and Mehra serve as national
principal investigators for the MOMENTUM 3 trial. Dr. Uriel is a consul-
tant to Thoratec, HeartWare, Abiomed, and Medtronic; and has received
a research grant from HeartWare. Dr. Mehra is a consultant to Thoratec,
HeartWare, St. Jude’s, Teva, Stealth Biopeptides, Medtronic, Boston
Scientiﬁc, and Johnson & Johnson (Janssen); has served as a consultant
to the National Institutes of Health/National Heart, Lung, and Blood
Institute in the capacity as chair of the data safety monitoring board of
the REVIVE-IT study; and is editor-in-chief of the Journal of Heart and
Lung Transplantation. Dr. Adatya has reported that he has no relation-
ships relevant to the contents of this paper to disclose.Continuous ﬂow (CF) LVADs have been adopted
widely as a bridge to transplantation or for permanent
lifetime therapy. Compared with medical therapy,
clinical outcomes with CF-LVADs increase 1- and
2-year survival (2). Yet, morbidity from device-related
complications remains high, characterized pre-
dominantly by complications related to the interface
between bleeding and thrombosis as well as the
patient-device interface. Principal hemocompatibility-
related adverse events encountered include bleeding,
thrombosis, and stroke, whereas right ventricular
HF (early and late) as well as infections (especially
driveline infections) constitute the foremost patient-
device related interactions (3–6). Thus, novel devices
with the aim of enhancing biocompatibility are
needed to move this rapidly evolving ﬁeld forward.In this issue of the Journal,Netuka et al. (7) report on
the ﬁrst-in-human experience of a new durable LVAD,
the HeartMate 3 (St. Jude Medical, Pleasanton, Cali-
fornia) in 50 patients from 10 centers within Europe,
Australia, and Canada. The HeartMate 3 LVAD is a new-
generation device, engineered with the promise of
enhanced hemocompatibility. This centrifugal ﬂow
device is miniaturized, uses magnetic levitation to
spin the rotor, and has large gaps between the pump
housing and perimeter of the rotor. The magnetic
levitation allows the rotor to stay in a stable position at
wide ranges of speed, while the enhanced gaps are
designed for improved blood ﬂow without encum-
bering increased shear stress on blood elements.
Two additional technical properties are embedded in
this device: internal sintering with textured titanium
microspheres to allow for a biocompatible surface,
and interestingly, an internal pulsatility function at a
rate of 30 beats/min with automatic speed changes.
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2591The primary reasoning behind this intrinsic pulse is
to reduce pump stasis. Whether this phenomenon
provides systemic beneﬁts as a circulatory pulse
mimic and decreases the incidence of gastrointestinal
bleeding secondary to arterial venous malformations
remains unknown.
The primary objective of this ﬁrst-in-human expe-
rience was to evaluate the early performance and
safety of this new left ventricular assist system. The
study met its pre-speciﬁed survival goal, with excel-
lent 1- and 6-month survival of 98% and 92%,
respectively. These ﬁndings are outlined in the
context of other similar experiences with currently
available LVADs as well as from the INTERMACS
(Interagency Registry for Mechanically Assisted
Circulatory Support) registry (Figure 1).FIGURE 1 Progressive Improvement in Outcomes of Patients Suppo
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INTERMACS ¼ Interagency Registry for Mechanically Assisted CirculatorAlthough we tend to classify patients into discrete
categories by intent of bridge to transplant or
permanent support, we recognize that such segrega-
tion in the advanced-stage HF patient can be rather
arbitrary. It has been demonstrated that 30% of pa-
tients listed with the initial intent to undergo heart
transplant remain on LVAD support for longer than
2 years, and as many as 44% of such individuals are
delisted from requiring transplantation (8). As such,
the initial HeartMate 3 LVAD experience was uniquely
constructed to enroll an “all-comers” population of
advanced stage HF. It is also known that transplant
ineligible patients tend to have modestly inferior
outcomes compared with the typically younger pop-
ulation of transplant candidates (with fewer comor-
bidities) who undergo LVAD implantation (2).rted With CF-LVADs for Advanced Heart Failure
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2592Thus, the clinical outcomes of the HeartMate 3
experience should be judged in light of the unique
“all-comer” population enrolled. In the INTERMACS
registry, 6-month survival in bridge to transplant is
90% and decreases to 83% in those designated as
destination therapy (2).
As we move the ﬁeld of mechanical circulatory
support forward, diminishing the reliance on segre-
gated indications and employing the use of LVAD
therapy as a step in the clinical journey of an
advanced-stage HF patient, tipping will be crucial. In
this regard, the pivotal U.S.-based MOMENTUM 3
(Multi-center Study of MagLev Technology in Patients
Undergoing MCS Therapy With HeartMate 3) clinical
trial purports to move this thought forward by eval-
uating 1,028 patients and randomizing them to the
HeartMate 3 versus the HeartMate II device with the
intent of evaluating any advanced-stage HF patient
deserving of such therapy to an evaluation endpoint
of freedom from death, pump exchange, or disabling
stroke at short-term (6 months) and long-term
(2 years) support (9).
More recently, the spotlight has been cast upon the
development of LVAD pump thrombosis that requires
pump exchanges, with consequent reduction in sur-
vival and increased disability from neurological
complications (8,10–12). The frequency of pump
thrombosis has been noted to increase between 6% to
12% in patients supported with HeartMate II LVAD
and 8% in those with an HVAD (HeartWare, Fra-
mingham, Massachusetts) (8,11,12–15). Encouragingly,
no device thrombosis or pump exchanges were seen
to occur by 6 months in the HeartMate 3 experience.
Coupled with this observation is the ﬁnding of sta-
bility in parameters of hemolysis, all providing evi-
dence of a trend toward enhanced hemocompatibility
with this LVAD. One must be cautious in exercising
excessive ebullience with this ﬁnding, because we are
looking at a small sample size of 50 patients with
limited duration of follow-up.
Neurological events, characterized by ischemic and
hemorrhagic strokes, are an “Achilles heel” of LVADs,
with a 2-year incidence of disabling stroke ranging
from 9 to 27 events/patient/year (16,17). Our under-
standing of this complication remains rudimentary,
with correlations of the type of device (higher inci-
dence with the HVAD), control of blood pressure
(better outcomes with lower pressure), and use of
antithrombotic therapy (6,17). Whether enhanced
hemocompatibility with the HeartMate 3 will also
serve in reducing this critical complication remains
uncertain. The observed rate of stroke in the current
study cohort was 12% (8% ischemic and 4% hemor-
rhagic stroke), and there was another 8% rate ofmilder neurological events such as seizures and
transient ischemic episodes within 6 months. It is
sobering to observe this higher than expected risk of
stroke; however, 1 stroke was related to an unusual
complication (contrast agent anaphylaxis) and
another to the learning curve of the surgical implant
technique (apical cuff bleeding and hypotension). It is
too scant an experience to provide conclusive direc-
tion in this regard, and the larger experience in
MOMENTUM 3 will be pivotal in enhancing our un-
derstanding of neurological complications with
CF-LVADs.
As new technology is introduced, it is not unusual
to observe a learning curve in its early application.
Evidence of this phenomenon is noted in the
HeartMate 3 series by the observation of a high rate of
early bleeding events, many of which required sur-
gical reintervention. It is also difﬁcult to predict
whether the standard anticoagulation protocols are
required, even as enhanced hemocompatibility is
observed. Thus, the learning curve is equally opera-
tional in the surgical technique as it is in the medical
management of the anticoagulation proﬁles, and
other factors such as blood pressure and blood vol-
ume control. Curiously, the rates of gastrointestinal
bleeding observed in this cohort appear to be lower
than those demonstrated in larger experiences
with conventional LVADs (18,19). It is known that
atrioventricular malformations and hemostatic ab-
errations by degradation of large multimers of von
Willebrand factor as a result of low systemic pulsa-
tility induced by CF-LVADs account for a signiﬁcant
predilection to gastrointestinal bleeding (18,19).
Whether enhanced hemocompatibility decreases this
outcome with the HeartMate 3 LVAD remains uncer-
tain. We urge caution in the interpretation of the
trend toward a lower gastrointestinal bleeding rate in
the current experience with the HeartMate 3, because
mechanistic insight about reduction of acquired von
Willebrand disease due to the reduced shear stress or
reduction the development of arterial venous mal-
formations and the effect of the intrinsic device arti-
ﬁcial pulse program is not provided.
As the ﬁeld of LVAD therapy advances, advanced-
stage HF patients tend to be referred before
end-organ failure sets in. In the current study, 40% of
the patients were in INTERMACS proﬁle 4 (those with
resting symptoms but not requiring inotropic sup-
port). Previous trials have enrolled a greater propor-
tion of patients that are in a higher INTERMACS
proﬁle with inotropic therapy dependency (20–22).
One could argue that the excellent 6-month survival
observed in the HeartMate 3 series is due to this
phenomenon. However, there is little difference in
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2593the quality-of-life parameters of INTERMACS 4
patients compared with proﬁle 3, and furthermore
(23), analyses of the INTERMACS registry suggest that
the outcome for an INTERMACS proﬁle 3 and 4 pa-
tient appears similar with device intervention (3). It is
in the cardiogenic shock patients (INTERMACS 1) or
those unstable on inotropic support (INTERMACS 2)
that the early hazard of worse outcome is noted. As
outcomes with available technology improve over
time, we may see earlier referral for evaluation and
consideration for therapy.
A gradual evolution, rooted in perseverance and
tolerance for clinical imperfection, has allowed the
ﬁeld of mechanical circulatory support to become aclinical reality. As engineering pursuits face clinical
reality, we are once again on the precipice of a new
technological advance in the ﬁeld. Whether this
promise becomes a clinical reality remains to be
proven. As Jean Piaget commented, “Scientiﬁc
thought, then, is not momentary; it is not a static
instance; it is a process” (24).
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